NIH supports milestone-driven development of non-addictive small molecule and biologic pain treatments, from lead optimization through Phase I testing, to prepare candidates for Phase II trials.
Funder: National Institutes of Health
Due Dates: February 19, 2027 (Application) | June 21, 2027 (Application) | October 20, 2027 (Application) | February 22, 2028 (Application) | June 20, 2028 (Application) | October 20, 2028 (Application) | February 20, 2029 (Final application)
Funding Amounts: $11 million estimated for 3 awards in FY 2027; project duration up to 5 years
Summary: Supports optimization and development of non-addictive small molecule and biologic pain therapeutics toward IND submission and Phase I testing.
Key Information: Applicants need an existing therapeutic lead, strong biological rationale, and established assays—not an initial hit-screening project.
The NIH HEAL Initiative, through NINDS and participating NIH institutes and centers, supports preclinical optimization and development of safe, effective, non-addictive pain therapeutics. The program aims to advance promising small molecule and biologic candidates toward readiness for Phase II trials through lead optimization, IND-enabling studies, pharmacodynamic or target-engagement biomarkers, IND preparation and submission, and Phase I testing.
Awards use a milestone-driven UG3/UH3 cooperative agreement with substantial NIH participation in planning and monitoring. Researchers may conduct development work themselves or collaborate with NIH-funded experts and contract research organizations. Each funded project receives a customized Lead Development Team to coordinate strategy and studies. The program seeks to strengthen academic–industrial partnerships and accelerate alternatives to addictive pain treatments.